Essai Clinique

Généré le 26 avr. 2025 à partir de

Titre	Cancers avec altérations moléculaires rares au Canada (CARMA) – Étude ouverte observationnelle en situation réelle (BROS)
Protocole ID	CARMA-BROS
ClinicalTrials.gov ID	NCT04151342
Type(s) de cancer	Autre
Phase	Autres
Type étude	Autre
Institution	CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE HOPITAL FLEURIMONT 3001 12e Avenue Nord, Sherbrooke, QC, J1H 5N4
Ville	
Investigateur principal	Dre Nicole Bouchard
Coordonnateur	Anick Champoux 819-346-1110 poste 12811
Statut	Actif en recrutement
But étude	This study will collect data on Canadian cancer patients that have uncommon/rare changes in their tumours, such as alterations/rearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR exon 20, ROS1, and BRAF, which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs). The goals for the study are to compare the natural history of such cancers and the treatment outcomes, including toxicities and patient-reported outcomes, for the different therapies.
Critères d'éligibilité	• Patients ≥ 18 years at cancer diagnosis • Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations • Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction [PCR] based next generation sequencing [NGS], immunohistochemistry [IHC], fluorescence in situ hybridization [FISH]) • Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment
Critères d'exclusion	• Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent